The U.S. Supreme Court has declined to hear an appeal from the Council for Responsible Nutrition (CRN), effectively upholding a New York law that restricts the sale of certain dietary supplements to individuals under the age of 18. This decision marks a significant moment in the ongoing debate surrounding the regulation of supplements, particularly those marketed for muscle building and weight loss, and their potential impact on young consumers.
Background of the Legal Challenge
The legal battle originated when New York enacted legislation aimed at curbing the sale of supplements deemed potentially harmful to minors. The law specifically targets products classified as "muscle-building" or "weight-loss" supplements, as well as those containing ingredients like creatine. The underlying rationale for this restriction, as articulated by proponents of the law, is the concern that such products may exacerbate or contribute to the development of eating disorders among adolescents.
The Council for Responsible Nutrition, a prominent trade association representing the dietary supplement industry, challenged the law, arguing that it was based on marketing claims rather than the actual effects of the products. CRN’s petition to the Supreme Court sought to review a previous decision by a lower court that had denied their request for a preliminary injunction, which would have temporarily halted the enforcement of the New York law.
The Scientific Basis Under Scrutiny
At the heart of the New York law’s scientific underpinning is research conducted by the Strategic Training Initiative for the Prevention of Eating Disorders (STRIPED), a research initiative based at Harvard University’s T.H. Chan School of Public Health. Led by researcher Bryn Austin, Ph.D., STRIPED’s work has been instrumental in highlighting potential risks associated with certain supplements.
Dr. Austin has asserted that the targeted supplements pose inherent dangers, citing concerns about undisclosed ingredients and their links to serious adverse health events. In communications with SupplySide Supplement Journal in 2022, Austin stated, "These products have been found again and again to contain a toxic brew of undisclosed ingredients linked to heart palpitations, cardiac arrest, stroke and even liver damage so extensive as to require organ transplant or resulting in death." This strong assertion forms a critical part of the justification for legislative action.
However, these claims have faced considerable pushback from within the supplement industry and from some scientific circles. Critics of Austin’s research often accuse her of selectively presenting data to support her conclusions. They argue that when the vast number of supplement servings consumed globally over decades is considered, the incidence of severe adverse events is statistically low, suggesting that supplements, as a category, are generally safe.
CRN’s Position and Expert Counterarguments
CRN has consistently maintained that the scientific basis for the New York law, and for Dr. Austin’s assertions, is flawed. The organization argues that public health policy should be driven by robust, peer-reviewed scientific evidence rather than assumptions or anecdotal reports.
Supporting CRN’s stance, researcher Susan Hewlings, Ph.D., published a review in the journal Nutrients in 2023. Her conclusion was unequivocal: "The evidence to date does not support a causative role for dietary supplements in eating disorders." This academic perspective directly challenges the premise upon which the New York law is built, suggesting that the link between these supplements and eating disorders is not scientifically established.
The Supreme Court’s Decision and its Implications
The Supreme Court’s decision not to hear CRN’s appeal means that the lower court’s ruling stands, allowing the New York law to remain in effect. While this does not constitute a ruling on the merits of CRN’s arguments, it significantly limits the immediate legal avenues for challenging such state-level regulations.
Steve Mister, president and CEO of CRN, expressed disappointment with the Supreme Court’s decision. He emphasized that the Court’s refusal to take the case "is not a ruling on the merits of our arguments, and it does not change our view that public-health policy should be grounded in evidence rather than assumptions about lawful products."
Mister indicated that CRN would continue its advocacy efforts to counter what it perceives as misguided state legislation. "The Supreme Court’s decision closes one legal avenue, but it does not resolve the underlying policy concerns," he stated. "CRN will continue working with lawmakers, regulators and other stakeholders to promote responsible, evidence-based policies that protect consumers without unnecessarily restricting access to lawful dietary supplements."
Broader Regulatory Landscape
This development occurs within a broader context of increasing regulatory scrutiny of the dietary supplement industry at both the state and federal levels. Experts have warned that a "crest of state rules" is still to come, indicating that New York’s law may be a harbinger of similar legislative efforts in other jurisdictions.
The Food and Drug Administration (FDA) also plays a crucial role in supplement oversight. Recent discussions at industry events, such as the AHPA Congress, have seen deputy directors outlining supplement priorities and emphasizing the importance of industry partnership. These dialogues highlight a tension between the desire for robust consumer protection and the industry’s call for regulations that are scientifically sound and do not unduly burden commerce.
Analysis of the Implications
The Supreme Court’s denial of CRN’s petition has several key implications:
- State-Level Regulatory Power: It reinforces the ability of individual states to enact specific regulations concerning the sale of certain products to minors, even if those products are generally legal for adult consumption. This could lead to a patchwork of differing regulations across the country, creating compliance challenges for national distributors.
- The Precautionary Principle: The decision suggests a greater willingness by courts to defer to legislative bodies that invoke the precautionary principle, especially when vulnerable populations like minors are involved. The assumption of potential harm, even if contested, can be sufficient grounds for regulation.
- Industry Strategy Shift: CRN’s stated intention to continue working with lawmakers and regulators indicates a shift in strategy. With the Supreme Court avenue closed for this specific challenge, the focus will likely move towards lobbying, public education, and potentially pursuing different legal arguments in future cases.
- Scientific Debate Continues: The underlying scientific debate regarding the link between certain supplements and eating disorders remains unresolved. The court’s decision does not settle this scientific controversy but rather allows a specific regulatory response to that controversy to stand. Future challenges may focus more directly on the scientific evidence itself, perhaps through different legal frameworks.
- Consumer Access: For consumers under 18 in New York, access to muscle-building and weight-loss supplements, or those containing creatine, will remain restricted. This directly impacts their ability to purchase these products, aligning with the state’s stated goal of protecting adolescent health.
Looking Ahead
The dietary supplement industry faces a dynamic regulatory environment. The New York law, now upheld by the Supreme Court’s inaction, represents a significant victory for public health advocates concerned about adolescent supplement use. For CRN and other industry groups, the path forward involves continued engagement in policy debates, a commitment to rigorous scientific research, and strategic legal challenges where appropriate. The fundamental tension between promoting consumer choice and ensuring public safety, particularly for young people, will undoubtedly continue to shape the future of supplement regulation. The industry’s ability to present compelling scientific evidence that refutes concerns about specific product categories will be crucial in navigating this evolving landscape.
